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Background: Affordable, accessible, and innovation-promoting pharmaceutical care 
is essential to the operation of a sustainable health system. External reference pricing 
(ERP), a common pharmaceutical policy in Europe, suffers today from indigenous weak-
nesses that may cause market distortions and barriers to care, burdening mostly the 
weak economies, and hence, raising ethical and political worrying.
Objectives and methods: A non-randomized experiment was conducted, in order 
to examine the influence of flexible and adaptable to health systems’ affordability ERP 
structures. Outcomes were assessed by measuring deviations from Greek prices’ level 
ex ante, as well as effects on pharmaceutical markets affiliated to the European ERP 
system.
results and conclusion: Pharmaceutical pricing models that fit prices to income and 
affordability are better in all aspects, as they produce fairer results, while resulting in 
low external costs for the European ERP network as a whole. Small sets of reference 
countries are preferred to large baskets, as they produce similar results, while presenting 
better qualities by increasing the flexibility of the reimbursement system and the trans-
parency of the market.
Keywords: external reference pricing, reimbursement, affordability, gDP, insurance price, greece
inTrODUcTiOn
The provision of affordable, accessible, and innovation-promoting pharmaceutical care services is an 
essential element of a sustainable health policy (1). In most European countries, the main purchaser 
of pharmaceuticals is the public sector (2), and in these quasi-monopsony conditions, national 
health services’ negotiating power is enhanced as to the determination of pharmaceutical prices. 
To this respect, the vast majority of European countries employ external reference pricing (ERP), 
a price-regulation method whereby a government considers the price of a medicine in a specified 
basket of countries in order to set its price (3). The application of ERP differs among countries, 
with regard to, e.g., basket size, basket composition, and re-referencing rates. Yet, a country’s ability 
to adjust medicinal prices to its income and affordability is limited due the method’s endogenous 
structural and functional characteristics.
External reference pricing is a univariate algebraic process that incorporates information solely 
on prices, not accounting for other key socioeconomic factors, e.g., health-care resources, health-
care structure, and demographic patterns (4), in the equation. In addition, the use of extensive 
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ERP baskets results in the increase of unmatched observations 
on currencies and medicinal properties (brand names, packag-
ing, etc.), encumbering the computational process, as ad  hoc 
studies illustrate (5–10). As a consequence, ERP’s sub-optimal 
design has a profound impact on health policies’ efficiency: it 
produces outcomes that present low adaptability to economies’ 
national income, increase market risks (e.g., arbitrage, medicine 
launch delays, slashed patent holders’ profitability and com-
petitiveness, etc.), raising barriers to existing therapies and to 
innovation as well (2). Nevertheless, the use of large baskets of 
countries remains a common European practice, given that 12 
European Union (EU-28) countries refer to a minimum of 15 
countries (11)1.
Greece is a dynamic player of the European ERP system. The 
implementation of ERP pertains to all on-patent medicines sold 
in the country, directly affecting reimbursement. According to 
legislation, the prices of on-patent medicines are set as the average 
of the three lowest ex-factory prices in the EU-28. Any available 
price (e.g., ex-factory, wholesale, retail, hospital, insurance) is col-
lected from official, published sources, and the necessary conver-
sion of retail or wholesale to ex-factory price is made according to 
methodology and rates determined by the National Organization 
for Medicines (EOF) (12). Using ERP, pharmaceutical prices are 
reviewed (re-pricing) twice per year. Following each re-pricing, 
the Positive Reimbursement List is also reviewed, in order to 
update reimbursed prices accordingly. At the same time, Greece is 
included in the ERP basket of half of the EU-28 countries [14 out 
of 28 (3)] and is among the countries with the highest frequency 
of re-referencing (biannual) (2).
Since the beginning of the economic crisis in 2010, pharma-
ceutical expenditure has been placed in the center of fiscal con-
solidation and has become inextricably linked to the level of the 
continuously decreasing Greek gross domestic product (GDP) 
(13). In particular, according to the target set by the Memorandum, 
public pharmaceutical expenditure must not exceed 1% of GDP. 
For this reason, a number of cost-containment measures target-
ing the prices of pharmaceuticals, such as flat price reductions, 
the implementation of multiple rebates/discounts and ERP have 
been applied to obtain quick reductions in public pharmaceutical 
spending and thus achieve the fiscal targets. In this context, fitting 
flexible and unerring pharmaceutical pricing models that take 
into account national income and financial indicators is a matter 
of national necessity. The present study investigates new meth-
odological pathways in the field of pharmaceutical pricing and 
reimbursement with aim to communicate additional evidence 
and inform health policy decision-making.
MeThODOlOgical Design
Outline and Objectives
We examine a flexible and adaptable to the payer’s affordability 
ERP structure, applying a non-randomized experiment, with 
Greek pharmaceutical prices forming the basis of the performed 
comparisons. The study is based on the working hypothesis that 
1 Based on calculations of the authors
the smaller the differential effects of interventions on Greek 
prices, the lower the pharmaceutical market risks, both internally 
and externally due to ERP’s spillover chain effects (6).
The analysis is conducted in two stages. The first stage exam-
ines the influence of small ERP baskets on the level of domestic 
pharmaceutical prices. The concept here is to remove procedural 
limitations, such as currency and price data incompatibility [as ex-
factory, retail, and hospital prices can currently enter the system 
(14)], by using a concise, and thus, flexible ERP design. The second 
stage proposes the establishment of a simple model/procedure that 
adapts prices to the country’s affordability level. This approach is 
a counterproposal to the current, extraordinary, and flat pharma-
ceutical policy measures that are being implemented in an effort 
to reduce excessive spending, but disturb the normal functioning 
of the pharmaceutical market and health care after all (15).
Data selection and arrangement
The analysis is based on a non-random experimental design, where 
data selection focuses on major pharmaceutical demand areas 
and meets certain product homogeneity requirements. The 
Greek Positive Reimbursement List formed the sampling frame 
of the selected medicines. Medicines were sorted according to 
their annual market share and a sample of 24% of the List’s 50 
top-selling medicines in 20122 (i.e., 12 out of 50) was taken. In 
addition, medicines were included in the analysis based on the 
following criteria: (1) identical properties (name, pharmaceutical 
form, content, packaging, and price type) among countries and 
(2) homogeneity of their prices’ measurement unit (ex-factory).
The selected experimental unit comprised a concise set of eight 
euro-zone members that practice ERP: Austria, France, Ireland, 
Italy, Portugal, Slovak Republic, Slovenia, and Spain. The group’s 
composition was assessed according to the specific financial, 
demographic, epidemiologic, and infrastructure criteria. Table 1 
provides this information for Greece. Statistical properties for 
the ex-factory price variable (i.e., descriptive measures of central 
tendency and variation) are presented in Table  2, by group of 
interest (Greece and the baskets).
Total observations (i.e., 72) are arranged by country and 
medicine, according to the [PN × m] block matrix cited in formula 
(Eq. 5). To achieve experiment repeatability, two data arrange-
ment scenarios were conducted, forming two experimental units, 
respectively. Each scenario thus pertained to one experimental 
unit and Greece, which was set as the comparison base. The 
experimental unit of Scenario 1 included the original basket 
of eight referenced countries. Scenario 2 reduced the basket to 
a subset of five countries (France, Ireland, Italy, Portugal, and 
Spain). Both scenarios involved equal number of observations, 
as presented in formula (Eq. 4).
Between-countries comparisons of price distributions are per-
formed using the statistical test of paired samples t-test of the SPSS 
software. The hypotheses of equality of mean ex-factory price 
between countries, as well as between a country and the basket 
mean are tested. The level of statistical significance is set at 0.05.
2 Based on records of Greece’s E-Government of Social Security (“IDIKA”) 
TaBle 2 | Basic descriptive statistics of the performance characteristic 
(ex-factory price).
scenario 1 scenario 2
greece
Sum (€)a 1,589.27 1,979.75
Median (€) 36.82 41.15
Arithmetic mean (€) 198.66 164.98
SD (€) 307.38 257.72
Minimum (€) 9.62 9.62
Maximum (€) 735.91 735.91
Range (€) 726.29 726.29
Coefficient of variation 1.54 1.56
Basket
Sum (€) 13,646.26 10,713.89
Median (€) 42.85 42.47
Arithmetic mean (€) 213.22 178.56
SD (€) 316.30 267.05
Minimum (€) 8.10 8.10
Maximum (€) 965.15 938.03
Range (€) 957.05 929.93
Coefficient of variation 1.48 1.50
aEqual to parameter “G” (Eq. 8).
TaBle 1 | socioeconomic indicators of reference countries and greece.
indicator (2013) greece Basket 1a Basket 2a
GDP euro per capita (chain linked volumes) 
(2010)f
16,800c 24,825d 26,440d
GDP euro per capitab (chain linked volumes) 
(2010)f
21,500 25,148 24,680
Total health expenditure per capita  
(current US$)g
2,146 3,229 3,374
Total health expenditure per capitab  
(current US$)g
2,924 3,420 3,693
Life expectancy at birth, total (years)h 81.0 80.5 81.4
Life expectancy at 65, total (years)i 20.2 20.0 20.7
Death rate, crude (per 1,000 people)j 10.0 9.0 8.8
Practicing doctors (per 1,000 people)k 6.3 3.6 3.6
Practicing nurses (per 1,000 people)k 3.6 7.6 7.8e
aMean value.
bData on 2009.
cProvisional.
dProvisional for Spain.
eData on Austria include nurses employed in hospital.
fEuropean Commission. Eurostat. Available from: http://ec.europa.eu/eurostat/tgm/
table.do?tab=table&init=1&plugin=1&pcode=tsdec100&language=en. Accessed 16 
January 2016.
gThe World Bank. Available from: http://data.worldbank.org/indicator/SH.XPD.PCAP. 
Accessed 10 January 2016.
hThe World Bank. Available from: http://data.worldbank.org/indicator/SP.DYN.LE00.IN. 
Accessed 10 January 2016.
iEuropean Commission. Eurostat. Available from: http://appsso.eurostat.ec.europa.eu/
nui/submitViewTableAction.do.
jThe World Bank. Available from: http://data.worldbank.org/indicator/SP.DYN.CDRT.IN. 
Accessed 10 January 2016.
kOECD (16).
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where n: the number of reference countries included in the basket; 
N: total number of countries, including Greece; m: the number of 
medicines; gi: the Greek price of the ith medicine (i = 1, 2, … , m); 
ri,j: referenced price: the price of the ith medicine in the jth refer-
ence country (i = 1, 2, … , m; j = 1, 2, … , n); [PN × m]: the general 
block matrix formula of Greek and referenced prices;
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The concise Basket Proposition
Differential effects of using concise baskets of reference countries 
on Greece’s prices are measured with the performance indica-
tor CBI (Eq. 6). CBI yields the difference in percentage points, 
between two quantities: the Greek sum of prices “G” and the 
expected sum of prices by basket, “E,” which is defined as the 
basket’s sum of pharmaceutical prices divided by the number of 
countries included in the basket (Eqs 7 and 8).
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where G: Greek sum of prices; E: expected sum of prices of a 
country included in the basket of Greece; and CBI: indicator of 
concise-basket effects.
application of insurance Price in 
Pharmaceutical reimbursement
We define as insurance price (“IP”) of a medicine the pharma-
ceutical reimbursement price that is adjustable to the country’s 
affordability level. Thus, IP is calculated as a function of two 
variables: the first variable is the expected sum of prices of a refer-
ence country included in the basket of Greece, i.e., the parameter 
“E,” as previously presented (Eq. 7) and the second is a weight 
that reflects Greece’s financial status. The financial status weight, 
denoted as “a,” relies on the concept of “affordability index” 
presented in the literature, which correlates countries’ mean 
GDP per capita to the corresponding European average (2). In 
particular, “a” is equal to Greece’s GDP per capita (GDPG) divided 
by the basket’s mean GDP per capita ( )GDPB  (Eqs 10–12), with 
“a < 1” indicating that Greek income is lower compared to the 
average income of the basket. IP equals the product of “a” and 
“E,” as shown in Eq. 9.
During the decade 2004–2013, Greece lost a fifth of its 
income (−19.6%, in per capita terms) (17). Non-stationarity 
of GDP per capita, however, renders the variable “a” time-
dependent. In addition, official and final data on GDPG are 
published with considerable delay, as according to Eurostat, 
the most recent finalized data on GDPG are traced back in 2010 
(17).3 To overcome these weaknesses which can bias both the 
process and the results, 2009 data have been used in the analy-
sis, as these data are final and also refer to a period before the 
economic crisis (17),4 enabling the drawing of more objective 
conclusions.
All involved GDP per capita indicators in the construction of 
variable “a” refer to 2009. The indicator of insurance price effects 
(IPI) yields the difference between the value of the insurance 
price “IP” and the Greek sum of prices “G,” in percentage points 
(Eq. 13).
 IP = ×a E  (9)
 
a a a=
1
2  
(10)
 a1 =GDPG  (11)
 a2 =GDPB  (12)
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3 Based on calculations of the authors
4 Based on calculations of the authors
where IP: insurance price; a: affordability weight; IPI: indicator 
of insurance price effects; GDPG: Greece’s GDP per capita; and 
GDPB: arithmetic mean of the GDP per capita of the basket.
estimation of external costs
External reference pricing models in essence constitute functions 
that calculate arithmetic means. Almost half of EU-28 (13/28) use 
the average price of their entire ERP basket, while others calculate 
the average price of a selected part of the basket (e.g., of a small 
subset of the lower prices, or the lowest value itself, etc.). Eight out 
of the 11 countries that refer to Greece in their ERP basket apply 
the first method (3). The impact (external costs) from Greece’s 
ERP process transformation (i.e., basket shrinking and “IP” 
application) on the affiliated European pharmaceutical markets 
was estimated by applying the average price of the whole basket 
(most common ERP method). Indicative values were produced 
using the pharmaceutical prices of this experiment. Three indices 
are presented in Eqs 14–16: “ERPC,” “EC1,” and “EC2.” ERPC 
measures the outcome of a typical ERP process for a randomly 
selected European country “C” that includes Greece in its basket; 
EC1 is an index that measures external costs resulting from the 
shrinking of Greece’s basket, and EC2 is an index that measures 
respective costs resulting from the application of Greece’s IP 
procedure. Detailed results are provided in Table 4.
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where ERPC: the outcome of a typical ERP process exercised by 
a random country “C,” which includes Greece in a basket of size 
“b”; pi: the medicinal price in the i referenced country included in 
C’s basket, i = 1, 2, … , b; b: the number of countries included in 
C’s basket; pG: the pi value when the referenced country is Greece; 
P: the sum of all pi’s, in the basket of size “b,” i = 1, 2, … , b; EC1: the 
index that measures external costs (in C) due to Greece’s basket 
shrinking; and EC1: the index that measures external costs (in C) 
due to Greece’s IP application.
resUlTs
The next paragraphs provide point estimates of the differential 
basket and reimbursement revision effects on Greece’s prices. 
Quantitative results for the potential impact of the proposed 
model on the country’s external environment are additionally 
presented. The microeconomic, macroeconomic, and demo-
graphic indicators that compose the research conditions under 
which the present experiment was conducted are also discussed.
TaBle 3 | Point-estimates of parameters and variables.
index Description scenario 1 scenario 2
G Sum of prices, Greece (€) 1,589.27 1,979.75
E Expected sum of prices, referenced 
country (€)
1,705.78 2,142.78
IP Insurance price (€) 1,486.08 1,831.86
CBI Indicator of concise-basket effects (%) +7.33 +8.24
IPI Indicator of insurance price effects (%) −6.49 −7.47
a Affordability weight (%) 87.12 85.49
TaBle 4 | Values of external-cost indices.
Medicinal product ec1 ec2
iD ex-factory price (€) S11 S12 S21 S22
Min Max % % % %
M1 12.93 36.43 na 1.63 na −1.47
M2 27.00 42.55 0.83 1.47 −0.74 −1.33
M3 39.78 52.87 0.74 1.29 −0.66 −1.17
M4 473.61 938.03 0.84 1.62 −0.74 −1.47
M5 35.70 42.60 na 1.73 na −1.57
M6 33.56 68.11 0.91 1.88 −0.80 −1.71
M7 33.07 42.38 0.82 1.48 −0.73 −1.34
M8 273.88 386.40 na 1.32 na −1.20
M9 32.96 81.70 0.75 1.22 −0.66 −1.11
M10 8.10 17.11 0.73 1.33 −0.65 −1.20
M11 34.97 117.39 na 1.21 na −1.10
M12 635.40 770.00 0.89 1.56 −0.79 −1.41
All 8.10 938.03 0.85 1.52 −0.76 −1.38
S11: EC1 – Scenario 1; S12: EC1 – Scenario 2; S21: EC2 – Scenario 1; S2: EC2 – Scenario 
2; na: not applicable.
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The formed baskets represent countries with similar demo-
graphic trends, as indicated by the data on life expectancy and 
death rates presented in Table 1. However, homogeneity between 
Greece and its baskets is reduced when health resources are taken 
into account. In particular, medical staff density in the population 
varies significantly between Greece and the baskets. Yet, this vari-
ation is independent from the baskets’ composition, considering 
Greece’s ranking above the OECD average with regards to this 
particular health-care parameter (16). The picture is completely 
reversed when the geographical dispersion of the nursing person-
nel is examined, with the number of practicing nurses per 1,000 
people less than half in Greece compared to the baskets (Table 1). 
Another difference between Greece and the baskets concerns 
total per capita health expenditure. Greece’s per capita health 
expenditure is below the corresponding average of the baskets. 
The latter is consistent with the rich theoretic background on the 
positive relation between GDP and public health expenditures 
per capita in OECD (18) and the fact that Greece’s income was 
lower in comparison with the baskets.
Income correlations constitute fundamental characteristics 
of this experiment where differential IP effects hinge on. The 
baskets represented countries of a higher income, on average, 
compared to Greece (Table  1). Basket 1 is placed below the 
European average (€25,500 and €28,300 in EU-28 and the 
Euro-area, respectively) (17), while basket 2 exceeds the EU-28 
average. The application of IP reduces the level of current home 
prices by 6.49–7.47% (Scenarios 1 and 2, respectively) (Table 3), 
causing though no severe impact abroad, considering the small 
effects that vary per product and overall between −1.71% (medi-
cine “M6,” Scenario 2) and −0.64% (medicine “M10,” Scenario 1), 
as Table 4 shows.
Regarding the performance characteristic, Greek prices were 
lower, compared to the mean price of the baskets, yet they pre-
sented higher variability, as indicated by the comparative central 
tendency and variation measures presented in Table  1. There 
were no statistical differences among the price distributions of the 
Scenario 1 (eight countries), except for the pair “France-Slovak 
Republic,” where French prices were lower (p-value = 0.05). In 
the smaller country set of the Scenario 2, Ireland appeared as 
an outlier, having statistically higher prices compared to France, 
Greece and Portugal (p-values 0.017, 0.022, and 0.024, respec-
tively). This scenario yielded statistically lower Greek prices by 
7.61% (p-value = 0.05) compared to the mean of the basket. CBI 
effects are in accordance with these statistical results, retaining 
however, their small range (<1%) across scenarios, considering 
that basket downsizing to five to eight countries caused Greek 
prices’ increase by 8.24% at the most (Table 3).
DiscUssiOn
External reference pricing, a common policy tool used worldwide 
to control prices of pharmaceuticals, is – in its present form – no 
longer considered sufficient in terms of operational efficiency and 
adaptability to payers’ available income, and has raised a lot of 
discussion and concerns among policy-makers, academia, and 
the industry. In this context, the present analysis produces new 
evidence regarding changes that could be incorporated in the 
ERP tool, to restore its efficacy.
A non-randomized experiment was conducted in order to 
examine the impact from the implementation of an ERP model 
that is flexible and adaptable to health systems’ affordability level. 
This experiment used Greek pharmaceutical prices as a key node 
of the European ERP network and tested the impact of ERP 
basket reconstruction and price-model fitting based on fiscal 
parameters. Results are examined with regard to the impact of 
differential price effects on both the Greek and other EU phar-
maceutical markets, assessing the proposed model in terms of its 
theoretic value and contribution.
Regarding the insurance price proposition, the model yielded 
small price effects in the two examined scenarios, despite the 
identified statistical differences between the involved price popu-
lations. Small price reductions though not only are consistent 
with the budgetary targets of the country but also deter collateral 
financial damages of restrictive pharmaceutical policies, such as 
public revenue losses, which is currently a serious fiscal issue in 
Greece (15).
Moreover, with its small price decreases, the proposed IP 
model poses a disincentive for parallel exports of pharmaceuticals, 
which in the past has been an intense phenomenon (19), restrict-
ing thus the role of arbitragers and thereby reducing the risk of 
pharmaceutical market shortages and barriers to pharmaceutical 
care (20). Considering barriers to medical care a topical health-
care issue in Europe (16), this model property is very important 
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from a general health policy perspective, and utilizable in Greece, 
where unmet health needs currently affect 9% of the population 
on average, while specific patient populations encounter even 
higher rates (e.g., 13% for multiple sclerosis patients) of barriers 
to medication (21).
In this context, the application of a bivariate pricing model that 
takes into account not only prices but also countries’ affordability 
level adjusts prices in the best interest of the public sector and 
the beneficiaries. Beyond these encouraging results, the model’s 
moderate effects also restrict unwanted price effects and potential 
damage in other countries to low percentages, i.e., around 1% (in 
absolute terms).
In support of these findings, which are consistent with other 
published studies (2), the estimated values of external cost indices 
(EI1 and EI2) are in fact overestimations. The mean size of EU 
baskets that include Greece equals 21 (11),5 whereas this work 
examined considerably smaller basket sizes (≤8 countries), which 
decrease the denominator of the quantity " "
p
P
G , thus increas-
ing the value of indices, “EC1” and “EC2” (Eqs 15 and 16).
In terms of the question of theoretic contribution, the presented 
model proposed the use of smaller baskets in ERP practicing. 
Taking into account the complex system of Greece with multiple 
5 Based on calculations of the authors 
sources of data, we conclude that structures that are more flexible 
bypass bureaucracy, enable computational transparency, and 
increase homogeneity of referenced countries. Furthermore, as 
the moderate increasing effects (<10%) of the basket-downsizing 
model on the Greek prices indicate, this improvement is achieved 
without causing serious price and market volatilities.
cOnclUsiOn
Technological progress, which shifts quality and prices of phar-
maceutical products upwards (18, 22, 23), as well as the rapid 
change in the demographic and epidemiological profile of the 
population (24), create a dynamic grid of long-term challenges 
for health-care systems, which are facing major pressures on their 
budgets. In light of the above, health-care decision makers must 
not stay inert. Advancing the quantity and quality of information 
incorporated in pharmaceutical pricing methodology, as sug-
gested by the present analysis, is a road that is worth being paved 
for all: the economy, the health-care system, and the health status 
of the population.
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